Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Double-blind, Randomised, Placebo-controlled, Crossover Study Investigating the Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome

NCT07257978 is registered in ClinicalTrials.gov with Fenix Innovation Group as lead sponsor.

NCT NCT07257978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07257978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Double-blind, Randomised, Placebo-controlled, Crossover Study Investigating the Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
Lead sponsor
Fenix Innovation Group
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
July 1, 2027
Completion date
October 1, 2028
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rett syndrome, rett syndrome with proven mecp2 mutation